紫杉醇和卡铂联合内生场热疗治疗晚期非小细胞肺癌临床分析

Clinical analysis of paclitaxel combined with carboplatin and hyperthermia in treatment of patients with advanced non-small cell lung cancer

目的评价紫杉醇、卡铂药物联合内生场热疗对晚期非小细胞肺癌的客观疗效及毒副作用。方法经病理学或细胞学证实的晚期非小细胞肺癌47例,给予紫杉醇90 mg/m2静滴,第1,8天;卡铂按浓度/时间曲线下面积(AUC)=5给药,静滴,第2天,28 d为1周期。同时配合内生场热疗,2次/周。结果总有效率为42.6%,中位缓解期为6个月,剂量限制性毒性为骨髓抑制。结论紫杉醇、卡铂联合内生场热疗治疗晚期非小细胞肺癌疗效较高,且毒性可以耐受,值得临床进一步研究应用。

Objective To evaluate the efficacy and toxicity of paclitexal combined with carboplatin and endogenetie field hyperthermia in treatment of advanced non-small cell lung cancer（NSCLC）. Methods Fourty-seven patients with locally advanced or metastatic NSCLC were enrolled into the study. The patients received paclitaxel 90mg/m2 on days 1,8, carboplatin at an AUC of 5 on day 2 and NRL-001 endogenetic field hyperthermia twice every week, 28 days comprised a cycle. Results The response rate was 42. 6%, median remission time was 6 months. The dose limiting toxicity was bone marrow suppression. Conclusions Paclitaxel combined with carboplatin and endogenetic field hyperthermia is an effective, well tolerated treatment for advanced NSCLC.